Ultragenyx sees enough in Angelman
The group buys out its partner Genetx, but inconsistent data spook investors.
The lowdown on high blood pressure
After Idorsia’s tease in resistant hypertension, data will soon emerge on other advanced assets, including long-acting RNA-based approaches.
Alnylam shoots for the heart
With readout of Apollo-B approaching, can Onpattro succeed where Bridgebio’s acoramidis failed?
